182 related articles for article (PubMed ID: 17032348)
1. Randomized comparison of two rescue therapies for Helicobacter pylori infection.
Wu DC; Hsu PI; Chen A; Lai KH; Tsay FW; Wu CJ; Lo GH; Wu JY; Wu IC; Wang WM; Tseng HH
Eur J Clin Invest; 2006 Nov; 36(11):803-9. PubMed ID: 17032348
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.
Kuo CH; Hu HM; Kuo FC; Hsu PI; Chen A; Yu FJ; Tsai PY; Wu IC; Wang SW; Li CJ; Weng BC; Chang LL; Jan CM; Wang WM; Wu DC
J Antimicrob Chemother; 2009 May; 63(5):1017-24. PubMed ID: 19246508
[TBL] [Abstract][Full Text] [Related]
3. Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies.
Wu DC; Hsu PI; Tseng HH; Tsay FW; Lai KH; Kuo CH; Wang SW; Chen A
Medicine (Baltimore); 2011 May; 90(3):180-185. PubMed ID: 21512411
[TBL] [Abstract][Full Text] [Related]
4. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
Nista EC; Candelli M; Zocco MA; Cremonini F; Ojetti V; Finizio R; Spada C; Cammarota G; Gasbarrini G; Gasbarrini A
Am J Gastroenterol; 2006 Sep; 101(9):1985-90. PubMed ID: 16968503
[TBL] [Abstract][Full Text] [Related]
5. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori.
Chuah SK; Hsu PI; Chang KC; Chiu YC; Wu KL; Chou YP; Hu ML; Tai WC; Chiu KW; Chiou SS; Wu DC; Hu TH
Helicobacter; 2012 Jun; 17(3):216-23. PubMed ID: 22515360
[TBL] [Abstract][Full Text] [Related]
7. [new one-week triple therapies with metronidazole for the eradication of Helicobacter pylori: clarithromycin or amoxycillin as the second antibiotic].
Gisbert JP; Boixeda D; Martín de Argila C; Redondo C; Moreno L; Abraira V; García Plaza A
Med Clin (Barc); 1998 Jan; 110(1):1-5. PubMed ID: 9527978
[TBL] [Abstract][Full Text] [Related]
8. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy.
Uygun A; Ozel AM; Yildiz O; Aslan M; Yesilova Z; Erdil A; Bagci S; Gunhan O
J Gastroenterol Hepatol; 2008 Jan; 23(1):42-5. PubMed ID: 17559359
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial.
Kuo CH; Hsu PI; Kuo FC; Wang SS; Hu HM; Liu CJ; Chuah SK; Chen YH; Hsieh MC; Wu DC; Tseng HH
J Antimicrob Chemother; 2013 Jan; 68(1):222-8. PubMed ID: 22984204
[TBL] [Abstract][Full Text] [Related]
10. Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection.
Murakami K; Okimoto T; Kodama M; Sato R; Miyajima H; Ono M; Inoue K; Watanabe K; Otsu S; Fujioka T
Helicobacter; 2006 Oct; 11(5):436-40. PubMed ID: 16961805
[TBL] [Abstract][Full Text] [Related]
11. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients.
Wang Z; Wu S
Singapore Med J; 2012 Apr; 53(4):273-6. PubMed ID: 22511052
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication.
Hsu PI; Lai KH; Lin CK; Chen WC; Yu HC; Cheng JS; Tsay FW; Wu CJ; Lo CC; Tseng HH; Yamaoka Y; Chen JL; Lo GH
Am J Gastroenterol; 2005 Nov; 100(11):2387-92. PubMed ID: 16279889
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
Zheng Q; Pan Y; Zhang L; Xiao SD
Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231
[TBL] [Abstract][Full Text] [Related]
15. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
Laine L; Estrada R; Trujillo M; Emami S
Am J Gastroenterol; 1997 Dec; 92(12):2213-5. PubMed ID: 9399755
[TBL] [Abstract][Full Text] [Related]
16. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
Park KN; Hahm JS; Kim HJ
Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
[TBL] [Abstract][Full Text] [Related]
18. Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy.
Kang JM; Kim N; Lee DH; Park YS; Kim YR; Kim JS; Jung HC; Song IS
Helicobacter; 2007 Dec; 12(6):623-8. PubMed ID: 18001404
[TBL] [Abstract][Full Text] [Related]
19. Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomized comparison between two 7-day triple therapies and a 14-day dual therapy.
de Boer WA; Haeck PW; Otten MH; Mulder CJ
Am J Gastroenterol; 1998 Jul; 93(7):1101-7. PubMed ID: 9672338
[TBL] [Abstract][Full Text] [Related]
20. [Eradication of Helicobacter pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2002].
Buzás GM; Józan J
Orv Hetil; 2004 Oct; 145(40):2035-41. PubMed ID: 15559530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
